Skip to main content Skip to main navigation menu Skip to site footer

High expression of CD73 as a negative predictor of clinical neoadjuvant chemotherapy response in triple-negative breast cancer

  • Silvia Khosasi ,
  • Ni Putu Sriwidyani ,
  • I Wayan Juli Sumadi ,
  • Ni Wayan Winarti ,
  • Ni Putu Ekawati ,
  • I Made Muliarta ,

Abstract

Background: Triple Negative Breast Cancer (TNBC) is one of the breast cancer subtypes with an aggressive clinical course and has a limited therapeutic strategy. Until now, conventional chemotherapy is still used as standard therapy, although it still has an inadequate therapeutic response. One of the chemoresistance mechanisms is likely due to the immunosuppressive effect of CD73-derived adenosine. This study aims to evaluate the high CD73 expression as a negative predictor of clinical neoadjuvant chemotherapy response in TNBC.

Methods: This study was a retrospective case-control study. A total of 46 TNBC patients who received neoadjuvant chemotherapy at Prof Dr. I.G.N.G Ngoerah's Hospital were enrolled. Twenty-three patients with positive neoadjuvant chemotherapy responded as the control group and 23 with negative neoadjuvant chemotherapy responded as the case group. Evaluation of CD73 expression was carried out by immunohistochemistry from a biopsy taken before the patient underwent neoadjuvant chemotherapy. CD73 expression was categorized into low and high based on staining intensity and percentage of the stained tumor cells. Data were analyzed using SPSS version 25.0 for Windows.

Results: Analysis showed a significant relationship between CD73 expression and clinical neoadjuvant chemotherapy response (OR=4.41; 95% CI=1.26-15.41; p=0.017). Multivariate analysis showed CD73 expression (AOR=4.88; 95%CI=1.08-21.99; p=0.039) and T stage (AOR=18.82; 95%CI=1.83-193.00; p=0.013) simultaneously affect clinical neoadjuvant chemotherapy response.

Conclusion: It can be concluded that high expression of CD73 and T stage is an independent predictor of negative clinical neoadjuvant chemotherapy response in TNBC patients.

Section

References

  1. Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016;8:93-107.
  2. Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol. 2018;29(4):1056-1062.
  3. Cerbelli B, Botticelli A, Pisano A, Pernazza A, Campagna D, De Luca A, et al. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Virchows Arch. 2020;476(4):569-576.
  4. Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9(2):176-198.
  5. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11(6):e0157368.
  6. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol. 2014;141(4):462-477.
  7. Chang-Qing Y, Jie L, Shi-Qi Z, Kun Z, Zi-Qian G, Ran X, et al. Recent treatment progress of triple negative breast cancer. Prog Biophys Mol Biol. 2020;151:40-53.
  8. Allard D, Turcotte M, Stagg J. Targeting A2 adenosine receptors in cancer. Immunol Cell Biol. 2017;95(4):333-339.
  9. Choi HR, Oh HK, Park SH, Jeong YJ. Expression of CD73 is associated with tumour progression and intratumoural inflammation in breast cancer. Asia Pac J Clin Oncol. 2020;18(1):35-43.
  10. Antonioli L, Novitskiy SV, Sachsenmeier KF, Fornai M, Blandizzi C, Haskó G. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov Today. 2017;22(11):1686-1696.
  11. Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43(8):723-737.
  12. Yang H, Yao F, Davis PF, Tan ST, Hall SRR. CD73, Tumour Plasticity and Immune Evasion in Solid Cancers. Cancers (Basel). 2021;13(2):177.
  13. Lafont V, Michaud HA, Bonnefoy N. CD73: a new biomarker in triple-negative breast cancer. Translational Cancer Research. 2018;7(Suppl 5):S594-S596.
  14. Khokher S, Qureshi MU, Mahmood S, Nagi AH. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev. 2013;14(5):3223-3228.
  15. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.
  16. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
  17. Wahidin M, Febrianti R, Susanty F, Hasanah SR. Twelve Years Implementation of Cervical and Breast Cancer Screening Program in Indonesia. Asian Pac J Cancer Prev. 2022;23(3):829-837.
  18. Andreopoulou E, Kelly CM, McDaid HM. Therapeutic Advances and New Directions for Triple-Negative Breast Cancer. Breast Care (Basel). 2017;12(1):21-28.
  19. Sanges F, Floris M, Cossu-Rocca P, Muroni MR, Pira G, Urru SAM, et al. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis. BMC Cancer. 2020;20(1):491.
  20. Sasanpour P, Sandoughdaran S, Mosavi-Jarrahi A, Malekzadeh M. Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients. Asian Pac J Cancer Prev. 2018;19(9):2423-2427.
  21. Ongko, N. Overekspresi Androgen Receptor (AR) sebagai Faktor Prediktif Respon Klinis Kemoterapi Neoadjuvan Negatif pada Triple Negative Breast Cancer. E-Jurnal Medika Udayana. 2021;10(8):33-38.
  22. Turiello R, Pinto A, Morello S. CD73: A Promising Biomarker in Cancer Patients. Front Pharmacol. 2020;11:609931.
  23. Soleimani A, Taghizadeh E, Shahsavari S, Amini Y, Rashidpour H, Azadian E, et al. CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives. J Cell Physiol. 2019;234(9):14622-14632.
  24. Loi S, Pommey S, Haibe-Kains B, Beavis PA. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013;110(27):11091-11096.
  25. Livingston-Rosanoff D, Schumacher J, Vande Walle K, Stankowski-Drengler T, Greenberg CC, Neuman H, et al. Does Tumour Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients. Clin Breast Cancer. 2019;19(6):e741-e747.
  26. Goorts B, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, de Boer M, et al. Clinical tumour stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017;163(1):83-91.
  27. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868.
  28. Udiyanto H, Mudigdo A, Sulistyowati S, Purwanto B, Widyaningsih V, Wasita B. A Cohort Study: Caspase-3 As Prognostic Factor of Radiation Therapy in The Advanced Stage of Cervical Cancer (IIB-IIIB) Patients. Bali Medical Journal. 2020;9(2):501-503.

How to Cite

Khosasi, S., Sriwidyani, N. P., Sumadi, I. W. J., Winarti, N. W., Ekawati, N. P. ., & Muliarta, I. M. (2023). High expression of CD73 as a negative predictor of clinical neoadjuvant chemotherapy response in triple-negative breast cancer. Indonesia Journal of Biomedical Science, 17(1), 94–99. https://doi.org/10.15562/ijbs.v17i1.418

HTML
193

Total
165

Share

Search Panel